Cargando…

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia

Ceftaroline is a new parenteral cephalosporin approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of complicated skin and soft tissue infections (cSSTIs) including those due to methicillin-resistant Staphylococcus aureus (MRSA), and communi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mpenge, Mbiye A, MacGowan, Alasdair P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396454/ https://www.ncbi.nlm.nih.gov/pubmed/25897241 http://dx.doi.org/10.2147/TCRM.S75412

Ejemplares similares

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010
por: Flamm, Robert K., et al.
Publicado: (2013)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
por: Cilloniz, Catia, et al.
Publicado: (2021)

Ceftaroline-related acute eosinophilic pneumonia
por: Min, Zaw, et al.
Publicado: (2021)

Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection
por: Kwak, Yee Gyung, et al.
Publicado: (2017)

Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012
por: Hoban, Daryl, et al.
Publicado: (2015)

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials
por: Wilcox, Mark, et al.
Publicado: (2021)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
por: Kuraieva, Alona, et al.
Publicado: (2023)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

100. Assessment of Emergency Department Prescribing Practices for Outpatient Treatment of Urinary Tract Infection, Community-Acquired Pneumonia, and Skin and Soft Tissue Infections
por: Thaller, Matthew, et al.
Publicado: (2021)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
por: Karki, Apurwa, et al.
Publicado: (2017)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Cardiovascular Complications in Community-Acquired Pneumonia
por: Desai, Antonio, et al.
Publicado: (2022)

Community-Acquired Skin and Soft Tissue Infections: Epidemiology and Management in Patients Presenting to the Emergency Department of a Tertiary Care Hospital
por: Alizai, Qaidar, et al.
Publicado: (2023)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Meropenem in the treatment of complicated skin and soft tissue infections
por: Fish, Douglas N
Publicado: (2006)

Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore
por: Chan, Monica, et al.
Publicado: (2017)

Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
por: Sánchez-García, Miguel, et al.
Publicado: (2020)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

Current role of community-acquired methicillin-resistant Staphylococcus aureus among children with skin and soft tissue infections
por: Teran, Carlos G., et al.
Publicado: (2012)

Community‐acquired Klebsiella pneumoniae systemic infection complicated with rhombencephalitis
por: Stanca, Delia‐Maria, et al.
Publicado: (2021)

The value of MALDI-TOF failure to provide an identification of Staphylococcal species direct from blood cultures and rule out Staphylococcus aureus bacteraemia: a post-hoc analysis of the RAPIDO trial
por: Hamilton, Fergus, et al.
Publicado: (2020)

Cardiac complications in community-acquired pneumonia and COVID-19
por: Feldman, C
Publicado: (2020)

Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics
por: Leong, Hoe Nam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j4umrgehv21rd5hiafvpdbgtqp